APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Based Preclinical CRO

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

Selected research

Market Outlook & Growth Opportunities

Global Oncology Based Preclinical CRO Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchOncology Based Preclinical CRO Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Based Preclinical CRO Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Oncology Based Preclinical CRO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Based Preclinical CRO Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Based Preclinical CRO Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

The industry's leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.

This report provides an overview of the global Oncology Based Preclinical CRO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Oncology Based Preclinical CRO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Based Preclinical CRO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncology Based Preclinical CRO market.

Oncology Based Preclinical CRO Segment by Company

Crown Bioscience

Charles River

ICON

Eurofins Scientific

Taconic Biosciences

Covance

EVOTEC

The Jackson Laboratory

MI Bioresearch

Champion Oncology

Wuxi AppTec.

Xentech

Living Tumor Laboratory

Oncology Based Preclinical CRO Segment by Type

Blood Cancer

Solid Tumors

Others

Oncology Based Preclinical CRO Segment by Application

In Vitro

In Vivo

Oncology Based Preclinical CRO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology Based Preclinical CRO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncology Based Preclinical CRO key companies, revenue, market share, and recent developments.

3. To split the Oncology Based Preclinical CRO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncology Based Preclinical CRO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Based Preclinical CRO significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Based Preclinical CRO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Based Preclinical CRO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Based Preclinical CRO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Based Preclinical CRO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Based Preclinical CRO industry.

Chapter 3: Detailed analysis of Oncology Based Preclinical CRO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncology Based Preclinical CRO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncology Based Preclinical CRO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Based Preclinical CRO Industry Trends Table 2. Oncology Based Preclinical CRO Industry Drivers Table 3. Oncology Based Preclinical CRO Industry Opportunities and Challenges Table 4. Oncology Based Preclinical CRO Industry Restraints Table 5. Global Oncology Based Preclinical CRO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Based Preclinical CRO Revenue Share by Company (2021-2026) Table 7. Global Oncology Based Preclinical CRO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncology Based Preclinical CRO Key Company Manufacturing Base & Headquarters Table 9. Global Oncology Based Preclinical CRO Company, Product Type & Application Table 10. Global Oncology Based Preclinical CRO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncology Based Preclinical CRO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Cancer Table 15. Significant Companies of Solid Tumors Table 16. Significant Companies of Others Table 17. Global Oncology Based Preclinical CRO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Oncology Based Preclinical CRO Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Oncology Based Preclinical CRO Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Oncology Based Preclinical CRO Sales Value Share by Type (2021-2026) Table 21. Global Oncology Based Preclinical CRO Sales Value Share by Type (2027-2032) Table 22. Significant Companies of In Vitro Table 23. Significant Companies of In Vivo Table 24. Global Oncology Based Preclinical CRO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Oncology Based Preclinical CRO Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Oncology Based Preclinical CRO Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Oncology Based Preclinical CRO Sales Value Share by Application (2021-2026) Table 28. Global Oncology Based Preclinical CRO Sales Value Share by Application (2027-2032) Table 29. Global Oncology Based Preclinical CRO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oncology Based Preclinical CRO Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Oncology Based Preclinical CRO Sales Value Share by Region (2021-2026) Table 32. Global Oncology Based Preclinical CRO Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Oncology Based Preclinical CRO Sales Value Share by Region (2027-2032) Table 34. Global Oncology Based Preclinical CRO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oncology Based Preclinical CRO Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Oncology Based Preclinical CRO Sales Value Market Share by Country (2021-2026) Table 37. Global Oncology Based Preclinical CRO Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Oncology Based Preclinical CRO Sales Value Market Share by Country (2027-2032) Table 39. Crown Bioscience Company Information Table 40. Crown Bioscience Business Overview Table 41. Crown Bioscience Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Crown Bioscience Oncology Based Preclinical CRO Product Portfolio Table 43. Crown Bioscience Recent Development Table 44. Charles River Company Information Table 45. Charles River Business Overview Table 46. Charles River Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Charles River Oncology Based Preclinical CRO Product Portfolio Table 48. Charles River Recent Development Table 49. ICON Company Information Table 50. ICON Business Overview Table 51. ICON Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. ICON Oncology Based Preclinical CRO Product Portfolio Table 53. ICON Recent Development Table 54. Eurofins Scientific Company Information Table 55. Eurofins Scientific Business Overview Table 56. Eurofins Scientific Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Eurofins Scientific Oncology Based Preclinical CRO Product Portfolio Table 58. Eurofins Scientific Recent Development Table 59. Taconic Biosciences Company Information Table 60. Taconic Biosciences Business Overview Table 61. Taconic Biosciences Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Taconic Biosciences Oncology Based Preclinical CRO Product Portfolio Table 63. Taconic Biosciences Recent Development Table 64. Covance Company Information Table 65. Covance Business Overview Table 66. Covance Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Covance Oncology Based Preclinical CRO Product Portfolio Table 68. Covance Recent Development Table 69. EVOTEC Company Information Table 70. EVOTEC Business Overview Table 71. EVOTEC Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. EVOTEC Oncology Based Preclinical CRO Product Portfolio Table 73. EVOTEC Recent Development Table 74. The Jackson Laboratory Company Information Table 75. The Jackson Laboratory Business Overview Table 76. The Jackson Laboratory Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. The Jackson Laboratory Oncology Based Preclinical CRO Product Portfolio Table 78. The Jackson Laboratory Recent Development Table 79. MI Bioresearch Company Information Table 80. MI Bioresearch Business Overview Table 81. MI Bioresearch Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. MI Bioresearch Oncology Based Preclinical CRO Product Portfolio Table 83. MI Bioresearch Recent Development Table 84. Champion Oncology Company Information Table 85. Champion Oncology Business Overview Table 86. Champion Oncology Oncology Based Preclinical CRO Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Champion Oncology Oncology Based Preclinical CRO Product Portfolio Table 88. Champion Oncology Recent Development Table 89. Wuxi AppTec. Company Information Table 90. Wuxi AppTec. Business Overview Table 91. Wuxi AppTec. Oncology Based Preclinical CRO Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 92. Wuxi AppTec. Oncology Based Preclinical CRO Product Portfolio Table 93. Wuxi AppTec. Recent Development Table 94. Xentech Company Information Table 95. Xentech Business Overview Table 96. Xentech Oncology Based Preclinical CRO Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 97. Xentech Oncology Based Preclinical CRO Product Portfolio Table 98. Xentech Recent Development Table 99. Living Tumor Laboratory Company Information Table 100. Living Tumor Laboratory Business Overview Table 101. Living Tumor Laboratory Oncology Based Preclinical CRO Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 102. Living Tumor Laboratory Oncology Based Preclinical CRO Product Portfolio Table 103. Living Tumor Laboratory Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Oncology Based Preclinical CRO Product Image Figure 2. Global Oncology Based Preclinical CRO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Based Preclinical CRO Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Based Preclinical CRO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Cancer Image Figure 8. Solid Tumors Image Figure 9. Others Image Figure 10. Global Oncology Based Preclinical CRO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oncology Based Preclinical CRO Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Oncology Based Preclinical CRO Sales Value Share by Type (2021-2032) Figure 13. In Vitro Image Figure 14. In Vivo Image Figure 15. Global Oncology Based Preclinical CRO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oncology Based Preclinical CRO Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oncology Based Preclinical CRO Sales Value Share by Application (2021-2032) Figure 18. Global Oncology Based Preclinical CRO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Oncology Based Preclinical CRO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Oncology Based Preclinical CRO Sales Value (2021-2032) & (US$ Million) Figure 21. North America Oncology Based Preclinical CRO Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Oncology Based Preclinical CRO Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Oncology Based Preclinical CRO Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Oncology Based Preclinical CRO Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Oncology Based Preclinical CRO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Oncology Based Preclinical CRO Sales Value (2021-2032) & (US$ Million) Figure 27. South America Oncology Based Preclinical CRO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Oncology Based Preclinical CRO Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Oncology Based Preclinical CRO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Cancer
  • Solid Tumors
  • Others
Applications
  • In Vitro
  • In Vivo
Companies covered
  • Crown Bioscience
  • Charles River
  • ICON
  • Eurofins Scientific
  • Taconic Biosciences
  • Covance
  • EVOTEC
  • The Jackson Laboratory
  • MI Bioresearch
  • Champion Oncology
  • Wuxi AppTec.
  • Xentech
  • Living Tumor Laboratory

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncology Based Preclinical CRO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncology Based Preclinical CRO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncology Based Preclinical CRO Market Dynamics
  1. 2.1 Oncology Based Preclinical CRO Industry Trends
  2. 2.2 Oncology Based Preclinical CRO Industry Drivers
  3. 2.3 Oncology Based Preclinical CRO Industry Opportunities and Challenges
  4. 2.4 Oncology Based Preclinical CRO Industry Restraints
3 Oncology Based Preclinical CRO Market by Company
  1. 3.1 Global Oncology Based Preclinical CRO Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Based Preclinical CRO Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Based Preclinical CRO Company Ranking (2024-2026)
  4. 3.4 Global Oncology Based Preclinical CRO Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncology Based Preclinical CRO Company Product Type and Application
  6. 3.6 Global Oncology Based Preclinical CRO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncology Based Preclinical CRO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncology Based Preclinical CRO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncology Based Preclinical CRO Market by Type
  1. 4.1 Oncology Based Preclinical CRO Type Introduction
  2. 4.1.1 Blood Cancer
  3. 4.1.2 Solid Tumors
  4. 4.1.3 Others
  5. 4.2 Global Oncology Based Preclinical CRO Sales Value by Type
  6. 4.2.1 Global Oncology Based Preclinical CRO Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oncology Based Preclinical CRO Sales Value by Type (2021-2032)
  8. 4.2.3 Global Oncology Based Preclinical CRO Sales Value Share by Type (2021-2032)
5 Oncology Based Preclinical CRO Market by Application
  1. 5.1 Oncology Based Preclinical CRO Application Introduction
  2. 5.1.1 In Vitro
  3. 5.1.2 In Vivo
  4. 5.2 Global Oncology Based Preclinical CRO Sales Value by Application
  5. 5.2.1 Global Oncology Based Preclinical CRO Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oncology Based Preclinical CRO Sales Value by Application (2021-2032)
  7. 5.2.3 Global Oncology Based Preclinical CRO Sales Value Share by Application (2021-2032)
6 Oncology Based Preclinical CRO Regional Value Analysis
  1. 6.1 Global Oncology Based Preclinical CRO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Based Preclinical CRO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncology Based Preclinical CRO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncology Based Preclinical CRO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncology Based Preclinical CRO Sales Value (2021-2032)
  7. 6.3.2 North America Oncology Based Preclinical CRO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncology Based Preclinical CRO Sales Value (2021-2032)
  10. 6.4.2 Europe Oncology Based Preclinical CRO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncology Based Preclinical CRO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncology Based Preclinical CRO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncology Based Preclinical CRO Sales Value (2021-2032)
  16. 6.6.2 South America Oncology Based Preclinical CRO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncology Based Preclinical CRO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncology Based Preclinical CRO Sales Value Share by Country, 2025 VS 2032
7 Oncology Based Preclinical CRO Country-level Value Analysis
  1. 7.1 Global Oncology Based Preclinical CRO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Based Preclinical CRO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncology Based Preclinical CRO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncology Based Preclinical CRO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncology Based Preclinical CRO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncology Based Preclinical CRO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncology Based Preclinical CRO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Crown Bioscience
  2. 8.1.1 Crown Bioscience Company Information
  3. 8.1.2 Crown Bioscience Business Overview
  4. 8.1.3 Crown Bioscience Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Crown Bioscience Oncology Based Preclinical CRO Product Portfolio
  6. 8.1.5 Crown Bioscience Recent Developments
  7. 8.2 Charles River
  8. 8.2.1 Charles River Company Information
  9. 8.2.2 Charles River Business Overview
  10. 8.2.3 Charles River Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Charles River Oncology Based Preclinical CRO Product Portfolio
  12. 8.2.5 Charles River Recent Developments
  13. 8.3 ICON
  14. 8.3.1 ICON Company Information
  15. 8.3.2 ICON Business Overview
  16. 8.3.3 ICON Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ICON Oncology Based Preclinical CRO Product Portfolio
  18. 8.3.5 ICON Recent Developments
  19. 8.4 Eurofins Scientific
  20. 8.4.1 Eurofins Scientific Company Information
  21. 8.4.2 Eurofins Scientific Business Overview
  22. 8.4.3 Eurofins Scientific Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eurofins Scientific Oncology Based Preclinical CRO Product Portfolio
  24. 8.4.5 Eurofins Scientific Recent Developments
  25. 8.5 Taconic Biosciences
  26. 8.5.1 Taconic Biosciences Company Information
  27. 8.5.2 Taconic Biosciences Business Overview
  28. 8.5.3 Taconic Biosciences Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Taconic Biosciences Oncology Based Preclinical CRO Product Portfolio
  30. 8.5.5 Taconic Biosciences Recent Developments
  31. 8.6 Covance
  32. 8.6.1 Covance Company Information
  33. 8.6.2 Covance Business Overview
  34. 8.6.3 Covance Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Covance Oncology Based Preclinical CRO Product Portfolio
  36. 8.6.5 Covance Recent Developments
  37. 8.7 EVOTEC
  38. 8.7.1 EVOTEC Company Information
  39. 8.7.2 EVOTEC Business Overview
  40. 8.7.3 EVOTEC Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 EVOTEC Oncology Based Preclinical CRO Product Portfolio
  42. 8.7.5 EVOTEC Recent Developments
  43. 8.8 The Jackson Laboratory
  44. 8.8.1 The Jackson Laboratory Company Information
  45. 8.8.2 The Jackson Laboratory Business Overview
  46. 8.8.3 The Jackson Laboratory Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 The Jackson Laboratory Oncology Based Preclinical CRO Product Portfolio
  48. 8.8.5 The Jackson Laboratory Recent Developments
  49. 8.9 MI Bioresearch
  50. 8.9.1 MI Bioresearch Company Information
  51. 8.9.2 MI Bioresearch Business Overview
  52. 8.9.3 MI Bioresearch Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MI Bioresearch Oncology Based Preclinical CRO Product Portfolio
  54. 8.9.5 MI Bioresearch Recent Developments
  55. 8.10 Champion Oncology
  56. 8.10.1 Champion Oncology Company Information
  57. 8.10.2 Champion Oncology Business Overview
  58. 8.10.3 Champion Oncology Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Champion Oncology Oncology Based Preclinical CRO Product Portfolio
  60. 8.10.5 Champion Oncology Recent Developments
  61. 8.11 Wuxi AppTec.
  62. 8.11.1 Wuxi AppTec. Company Information
  63. 8.11.2 Wuxi AppTec. Business Overview
  64. 8.11.3 Wuxi AppTec. Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Wuxi AppTec. Oncology Based Preclinical CRO Product Portfolio
  66. 8.11.5 Wuxi AppTec. Recent Developments
  67. 8.12 Xentech
  68. 8.12.1 Xentech Company Information
  69. 8.12.2 Xentech Business Overview
  70. 8.12.3 Xentech Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Xentech Oncology Based Preclinical CRO Product Portfolio
  72. 8.12.5 Xentech Recent Developments
  73. 8.13 Living Tumor Laboratory
  74. 8.13.1 Living Tumor Laboratory Company Information
  75. 8.13.2 Living Tumor Laboratory Business Overview
  76. 8.13.3 Living Tumor Laboratory Oncology Based Preclinical CRO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Living Tumor Laboratory Oncology Based Preclinical CRO Product Portfolio
  78. 8.13.5 Living Tumor Laboratory Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst